Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. (Q30376550)

21 June 2017

1 reference

title

Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. (English)

1 reference

21 June 2017

1 reference

Otfried Kistner

1 reference

21 June 2017

P Noel Barrett

1 reference

21 June 2017

Wolfgang Mundt

1 reference

21 June 2017

M Keith Howard

series ordinal

1 reference

21 June 2017

publication date

1 May 2009

1 reference

Expert Review of Vaccines

21 June 2017

published in

1 reference

21 June 2017

1 reference

21 June 2017

1 reference

21 June 2017

page(s)

607-618

1 reference

Cultivation of the Lansing Strain of Poliomyelitis Virus in Cultures of Various Human Embryonic Tissues

21 June 2017

cites work

1 reference

Polio vaccines, Simian Virus 40, and human cancer: the epidemiologic evidence for a causal association

21 January 2018

1 reference

The serial cultivation of human diploid cell strains

21 January 2018

1 reference

Rabies Vaccine Prepared in Human Cell Cultures: Progress and Perspectives

21 January 2018

1 reference

Tumorigenicity of Vero cells.

21 January 2018

1 reference

The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines.

21 January 2018

1 reference

Fifteen years of experience with Vero-produced enhanced potency inactivated poliovirus vaccine

21 January 2018

1 reference

Development of a mammalian cell (Vero) derived candidate influenza virus vaccine

21 January 2018

1 reference

A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses

21 January 2018

1 reference

Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses.

21 January 2018

1 reference

A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

21 January 2018

1 reference

Rotavirus vaccines: an overview

21 January 2018

1 reference

The new pentavalent rotavirus vaccine composed of bovine (strain WC3) -human rotavirus reassortants

21 January 2018

1 reference

Clinical trials of rotavirus vaccines in Europe

21 January 2018

1 reference

Live attenuated human rotavirus vaccine, Rotarix

21 January 2018

1 reference

Rotarix (RIX4414): an oral human rotavirus vaccine

21 January 2018

1 reference

Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis

21 January 2018

1 reference

Development of Vero cell-derived inactivated Japanese encephalitis vaccine

21 January 2018

1 reference

Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses

21 January 2018

1 reference

Japanese encephalitis vaccine in travelers

21 January 2018

1 reference

Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial

21 January 2018

1 reference

Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine

21 January 2018

1 reference

A purified inactivated Japanese encephalitis virus vaccine made in Vero cells.

21 January 2018

1 reference

A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis.

21 January 2018

1 reference

Long-term stability of Vero cell-derived inactivated Japanese encephalitis vaccine prepared using serum-free medium

21 January 2018

1 reference

Non-clinical and phase I clinical trials of a Vero cell-derived inactivated Japanese encephalitis vaccine

21 January 2018

1 reference

Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis

21 January 2018

1 reference

Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis anti

21 January 2018

1 reference

Dengue vaccines approach the finish line

21 January 2018

1 reference

Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1

21 January 2018

1 reference

Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3′ untranslated region (3′-UTR) or by exchange of the DENV-3 3′-UTR with that of DENV-4

21 January 2018

1 reference

The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers.

21 January 2018

1 reference

rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults.

21 January 2018

1 reference

rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers

21 January 2018

1 reference

Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates

21 January 2018

1 reference

A live, attenuated recombinant West Nile virus vaccine

21 January 2018

1 reference

ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy

21 January 2018

1 reference

Vero cell-derived inactivated West Nile (WN) vaccine induces protective immunity against lethal WN virus infection in mice and shows a facilitated neutralizing antibody response in mice previously immunized with Japanese encephalitis vaccine

21 January 2018

1 reference

Emerging zoonoses: the challenge for public health and biodefense

21 January 2018

1 reference

Coronavirus as a possible cause of severe acute respiratory syndrome

21 January 2018

1 reference

The preclinical testing of a formaldehyde inactivated Ross River virus vaccine designed for use in humans

21 January 2018

1 reference

Re-emergence of chikungunya virus in India

21 January 2018

1 reference

Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak

21 January 2018

1 reference

Chimeric alphavirus vaccine candidates for chikungunya

21 January 2018

1 reference

Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice.

21 January 2018

1 reference

Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine

21 January 2018

1 reference

Evidence for host-cell selection of influenza virus antigenic variants

21 January 2018

1 reference

Structural changes in the haemagglutinin which accompany egg adaptation of an influenza A(H1N1) virus

21 January 2018

1 reference

Egg Fluids and Cells of the Chorioallantoic Membrane of Embryonated Chicken Eggs Can Select Different Variants of Influenza A (H3N2) Viruses

21 January 2018

1 reference

The role of amniotic passage in the egg-adaptation of human influenza virus is revealed by haemagglutinin sequence analyses

21 January 2018

1 reference

Protein Synthesis in Vero Cells Abortively Infected with Influenza B Virus

21 January 2018

1 reference

Abortive Infection of Vero Cells by an Influenza A Virus (FPV)

21 January 2018

1 reference

Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics.

21 January 2018

1 reference

Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system.

21 January 2018

1 reference

Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERV.09.19

1 reference

21 June 2017

1 reference